Naltrexone-bupropion for the treatment of binge eating disorder: a systematic review and meta-analysis.

ABSTRACT:

Objective

This meta-analysis aimed to evaluate the efficacy of naltrexone-bupropion in binge eating disorder patients.

Methods

We searched MEDLINE, Embase, and Cochrane databases up to February 2025 for randomized controlled trials comparing naltrexone-bupropion to placebo. The primary outcome was binge eating frequency. Secondary outcomes included body mass index, body weight, depression, lipid profile, and glycated hemoglobin levels. Mean differences (MD) with 95%CI were pooled using appropriate methods.

Results

Three trials were included with a total of 177 patients, of whom 49% received the intervention. There was no significant difference between groups for binge eating (MD -1.25; 95%CI -5.61 to 3.11; 0 = 0.57), body mass index (MD -2.24; 95%CI -8.01 to 3.53; p =

SUBMITTER: Marcal JBC 

PROVIDER: S-EPMC12815388 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature